; (D) an anonymized summary of the reports filed with the Commission pursuant to subsection (a) for the reporting year; (E) an analysis of the requirements of this Act and whether the implementation of such requirements leads to mergers (including horizontal mergers or vertical mergers) amongst any pharmacy benefit managers, or any pharmacy benefit manager that owns, controls, or is affiliated with a pharmacy, or any pharmacy benefit manager that owns, controls, or is affiliated with a health plan, and the effect of such merger (including the likelihood of a substantial decrease in competition or the potential for a monopoly); and (F) policy or legislative recommendations to strengthen any enforcement action relating to a violation of this Act, including recommendations to include additional prohibited conduct in section 2(a), and recommendations to encourage more competition and decrease the likelihood of a monopoly in the pharmaceutical supply chain. (2) Formulary design or placement practices Not later than 1 year after the date of enactment of this Act, the Commission shall submit to the Committee on Commerce, Science, and Transportation of the Senate, the Committee on Finance of the Senate, the Committee on Health, Education, Labor, and Pensions of the Senate, the Committee on Ways and Means of the House of Representatives, and the Committee on Energy and Commerce of the House of Representatives a report that addresses the policies, practices, and role of pharmacy benefit managers (including their affiliates, subsidiaries, and agents) regarding formulary design or placement, including— (A) whether pharmacy benefit managers (including their affiliates, subsidiaries, and agents) use formulary design or placement to increase their gross revenue without an accompanying increase in patient access or decrease in patient cost